Loss of exclusivity is predictable, yet many portfolios treat it as a surprise. Understanding how generic entry plays out in a given market is the starting point for both originator and generic strategies.
What determines when generics enter
Timing depends on the interaction of regulatory data and market protection periods, patents and supplementary protection certificates, and the pace at which generic applicants obtain authorisation and reimbursement. These vary by product and market, and the EU pharma reform may alter the protection periods that apply, so planning should rely on current legal advice rather than assumptions carried over from past products.
How uptake is driven
Generic entry does not automatically translate into rapid generic uptake. Uptake depends on policy and practice:
- Pricing rules: many systems link the price of the originator to generic entry, which reduces reimbursed prices.
- Prescribing incentives: in Greece, targets for the share of generics in each physician’s prescriptions, introduced in 2014, were one such lever.
- Substitution: pharmacist substitution rules and patient co-payment differences shape what is dispensed.
- Hospital tenders: in the hospital sector, price competition via tenders can move volume quickly.
For originators
- Model the post-expiry revenue curve for each market separately, not as a single global assumption.
- Consider lifecycle options carefully, including new indications, formulations and evidence generation, and test whether payers would value them.
- Plan supply and communication so that patients and prescribers are not caught out by switches.
For generic companies
- Choose products by assessing how many competitors are likely, not just by the size of the originator’s sales.
- Build the regulatory dossier, including bioequivalence where required, early enough to be ready on the first day permitted.
- Understand the pricing and reimbursement rules that apply to a new entrant, since the first generic may be priced against a reference that changes after entry.
- Secure reliable supply, because shortages and quality failures damage credibility with both authorities and tenders.
Treat each market as its own case
The same molecule can show very different dynamics across countries because of pricing law, prescribing culture and hospital procurement. Generalisations from one market should be tested before being relied upon in another.
A short checklist
- When exactly are protection periods expected to end for each market?
- What do current pricing rules say about the price after generic entry?
- Which prescribing, substitution and tender mechanisms will drive uptake?
- Is the regulatory and supply plan ready for the first permitted day of entry?
Teams that answer these questions market by market tend to forecast more realistically and react earlier.
How PQRA helps
PQRA supports both originators and generic companies on the regulatory and access side of this transition: marketing authorisation strategy, lifecycle and variation planning, pricing and reimbursement procedures in Greece, and launch readiness. Commercial forecasting remains with your own teams.
Ready to discuss your market access plan? Contact PQRA to talk through your product and your target markets.


No responses yet